BioCentury
ARTICLE | Clinical News

Sellas rises on Phase IIb TNBC data

April 2, 2018 11:11 PM UTC

Sellas Life Sciences Group Inc. (NASDAQ:SLS) gained $5.20 (151%) to $8.65 on Monday after reporting interim Phase IIb data showing that NeuVax nelipepimut-S plus Herceptin trastuzumab given in the adjuvant setting significantly improved median disease-free survival (DFS) in triple-negative breast cancer patients compared with Herceptin plus GM-CSF (HR=0.26, p=0.023).

An independent DSMB conducted the prespecified interim analysis of the trial after a median follow-up of 19 months. NeuVax plus Herceptin also led to a 70.4% reduction in the relative risk of recurrence vs. the control arm in the 98-patient TNBC cohort...